Using an AI-driven drug discovery process, the drug known as vorinostat was identified as a promising treatment for Rett syndrome.

A new treatment option, Datroway (datopotamab deruxtecan or Dato-DXd), is now available for people with non-small cell lung ...

Rett syndrome is a devastating rare genetic childhood disorder primarily affecting girls. Merely 1 out of 10,000 girls are ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 12 Small Cap Stocks with High Upside Potential. On June 4, the company ...

The FDA has granted accelerated approval to datopotamab deruxtecan (Datroway) for adults with locally advanced or metastatic non-small cell lung cancer that carries an EGFR mutation and has progressed ...

GSK has made the decision to withdraw Jesduvroq (daprodustat) from the US market. Approved in 2023, Jesduvroq, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), is indicated ...

GlobalData’s report assesses how Daprodustat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here. GlobalData tracks drug-specific ...

This is the second drug in this new class to gain approval for this indication. The first oral HIF-PH agent, daprodustat (Jesduvroq), was approved for adults with CKD-related anemia on dialysis by ...

In February 2023, the FDA approved oral daprodustat for anemia caused by chronic kidney disease for adults on dialysis. 16-17 Medication Class: Hypoxia-inducible factor prolyl hydroxylase inhibitor ...